Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Kakolyris

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 25, 2002
Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II studyD Mavroudis, G Pavlakou, G Blazoyiannakis, et al.
British Journal of Cancer|March 2, 2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)J Souglakos, N Androulakis, K Syrigos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2007
Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancerN Xenidis, V Markos, S Apostolaki, et al.
Histopathology|December 31, 1998
Expression and subcellular localization of human AP endonuclease 1 (HAP1/Ref-1) protein: a basis for its role in human diseaseS Kakolyris, L Kaklamanis, A Giatromanolaki, et al.
Lung Cancer (Amsterdam, Netherlands)|May 30, 2008
Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II studyI Boukovinas, J Souglakos, D Hatzidaki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG)C Kouroussis, E Xydakis, A Potamianou, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2001
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II studyS Kakolyris, E Papadakis, X Tsiafaki, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2001
Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trialV Georgoulias, G Samonis, E Papadakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 1998
Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II studyN Androulakis, C Kouroussis, S Kakolyris, et al.
Seminars in Oncology|August 1, 1997
Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary resultsV Georgoulias, C Kourousis, N Androulakis, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Lung Cancer (Amsterdam, Netherlands)|December 25, 2002
Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II studyD Mavroudis, G Pavlakou, G Blazoyiannakis, et al.
British Journal of Cancer|March 2, 2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)J Souglakos, N Androulakis, K Syrigos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2007
Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancerN Xenidis, V Markos, S Apostolaki, et al.
Histopathology|December 31, 1998
Expression and subcellular localization of human AP endonuclease 1 (HAP1/Ref-1) protein: a basis for its role in human diseaseS Kakolyris, L Kaklamanis, A Giatromanolaki, et al.
Lung Cancer (Amsterdam, Netherlands)|May 30, 2008
Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II studyI Boukovinas, J Souglakos, D Hatzidaki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG)C Kouroussis, E Xydakis, A Potamianou, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2001
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II studyS Kakolyris, E Papadakis, X Tsiafaki, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2001
Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trialV Georgoulias, G Samonis, E Papadakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 1998
Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II studyN Androulakis, C Kouroussis, S Kakolyris, et al.
Seminars in Oncology|August 1, 1997
Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary resultsV Georgoulias, C Kourousis, N Androulakis, et al.
Pageof 13